Bicara Therapeutics is a clinical-stage biotech company pioneering bifunctional antibodies for targeted tumor modulation. Founded in 2020, the company has a global team of over 100 employees headquartered in Boston, with a focus on advancing its lead asset, ficerafusp alfa.